Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes
Investigation of the Effect of Fasting Duration and Temporary Withholding of Subcutaneous Administration of Zenagamtide on Retained Gastric Contents in Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The purpose of this clinical study is to find out how the duration of fasting (not eating or drinking, except for water) and pausing of treatment with zenagamtide medication affect the amount of food and liquid left in the stomach of people using zenagamtide.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Novo Nordisk
- Telefonnummer: (+1) 866-867-7178
- E-post: clinicaltrials@novonordisk.com
Studiesteder
-
-
California
-
Cypress, California, Forente stater, 90630
- Altasciences Clinical LA, Inc.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 and older at the time of signing the informed consent.
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.
For participants with type 2 diabetes (T2D)
- Diagnosed with type 2 diabetes (T2D) more than (>) 180 days before screening.
- No treatment with oral anti-diabetic drugs except metformin. Treatment with metformin should be stable (dose and dosing frequency) for at least 90 days before screening.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders as judged by the investigator.
- Diagnosed with or suspected to suffer from gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or when in supine position.
- Use of other medications known to affect the motility of the stomach.
- Inability to lie in the right lateral decubitus position for gastric ultrasonography.
For participants without T2D - Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) [48 millimoles per mole (mmol/mol)] at screening.
For participants with T2D
- HbA1c ≥ 10.5 % (91 mmol/mol) at screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Zenagamtide
Participants will receive zenagamtide once weekly subcutaneously (s.c.). |
Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors in one of the body parts: thigh, abdomen or upper arm. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as milliliter per kilogram (mL/kg) |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Gastric volume after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Gastric volume after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- NN9490-8698
- U1111-1336-6870 (Annen identifikator: World Health Organization (WHO))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .